Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of B-cell chronic lymphocytic leukemia (CLL) requiring therapy and meeting the following criteria:~  * Previously untreated disease~ * Peripheral blood morphology, excluding other leukemia and low-grade lymphoma in leukemic phase~ * Cell markers: CD5+, CD23+, SmIg (weak), CD79b-, FMC7-~ * Persistent lymphocytosis (greater than 10,000/mm\^3)~ * At least 40% bone marrow infiltration~* Stage 0 or I progressive disease indicated by at least one of the following:~  * Persistent rise in lymphocyte count with doubling time less than 12 months~ * Downward trend in hemoglobin and/or platelet count~ * At least 50% increase in size of liver and/or spleen and/or lymph nodes~ * Appearance of lymphadenopathy, hepatomegaly, or splenomegaly~ * Constitutional symptoms caused by disease~    * Pyrexia~   * Night sweats~   * Weight loss OR~* Stage II or III~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* See Disease Characteristics~Hepatic:~* Bilirubin no greater than 2 times upper limit of normal (ULN)\*~* SGOT/SGPT no greater than 2 times ULN\* NOTE: \* Unless due to CLL~Renal:~* Creatinine clearance at least 30 mL/min~Other:~* No other cancer or life-threatening disease~* Not pregnant~* Fertile patients must use effective contraception during and for 6 months after study therapy~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* No concurrent corticosteroids (e.g., dexamethasone) as antiemetics~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).